Lornoxicam injection is inferior to betamethasone in the treatment of subacromial impingement syndrome

Aksakal, Murat; Ermutlu, Cenk; Özkaya, Güven; Özkan, Yüksel

doi:10.1007/s00132-016-3302-5

Cited by 14 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Aksakal et al (18) investigated the effect of betamethasone injection and lornoxicam in performance of patients with shoulder impingement syndrome. They reported that a single dose of subacromial lornoxicam injection had a better improvement in comparison with betamethasone at the second week.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Efficacy of Ketorolac, Triamcinolone and Betamethasone Injections in the Treatment of Shoulder Impingement Syndrome

Abolhasani¹,

Falsafi²,

Khafri³

et al. 2019

jemds

View full text Add to dashboard Cite

BACKGROUND There is controversial evidence regarding subacromial injections of nonsteroidal anti-inflammatory drugs and corticosteroid providing pain relief and restoration of function in shoulder impingement syndrome. We wanted to assess and compare the efficacy of subacromial ketorolac and steroids injections in treatment of patients with impingement syndrome. METHODS This study was a double-blind randomized controlled trial. The intervention groups included: A) Ketorolac; B) Triamcinolone; C) Betamethasone LA. The patients' pain was recorded based on Visual Analogue Scale system, and performance of patients was recorded based on Oxford Shoulder Score in 0, 2, 4, and 6 weeks. One-way ANOVA, chi-square test and repeated measurement were used to compare and analyse obtained results. RESULTS One hundred five patients were enrolled in the study. Three groups (each one containing 35 patients) were compatible in age and gender. Performance of patients was significantly improved in all three groups over time (p<0.001). The mean pain score of all three groups was significantly decreased over time in the three groups (p<0.001). No significant difference was found for pain scores between the groups at different follow-ups. CONCLUSIONS The results of present study showed that ketorolac, triamcinolone, and betamethasone are equally effective in improving and reducing patients' performance and pain, respectively, in treatment of impingement syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In addition, lornoxicam injection improved performance of patients faster. (18) In the above studies, it has been argued that NSAIDs respond better than corticosteroids. In contrast, in a study by Onat et al, they found that the kinesiotaping group and the corticosteroid group had a better range of motion than the NSAID group.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Efficacy of Ketorolac, Triamcinolone and Betamethasone Injections in the Treatment of Shoulder Impingement Syndrome

Abolhasani¹,

Falsafi²,

Khafri³

et al. 2019

jemds

View full text Add to dashboard Cite

show abstract

“…They concluded that, although a single subacromial lornoxicam injection provides rapid functional recovery, which partially extends into the intermediate term, its results are inferior to betamethasone and it may be an alternative only in patients where corticosteroids are contraindicated. [ 30 ]…”

Section: Discussionmentioning

confidence: 99%

Comparison of subacromial ketorolac injection zversus corticosteroid injection in the treatment of shoulder impingement syndrome

et al. 2017

View full text Add to dashboard Cite

Objective:Subacromial impingement syndrome is the most common cause of shoulder pain and restriction in range of motion in the world. The aim of this study was to compare the efficacy of subacromial injection of ketorolac with the injection of corticosteroid for the treatment of subacromial impingement syndrome.Methods:A total of forty patients were randomly allocated into two groups. Group A received 40 mg of methylprednisolone and Group B received 60 mg of ketorolac as a subacromial injection along with lidocaine. Each patient was evaluated in terms of visual analog scale (VAS) for evaluating pain and Constant's score for function evaluation (pain, activity level, and range of motion with standard goniometry). The patients were re-examined 1 and 3 months after intervention. All the patients educated for simple home exercise.Findings:At 1 and 3 months of follow-up, both treatment arms resulted in an increased range of motion and decreased pain. The difference between the groups was not statistically significant (P > 0.05). In ketorolac group, mean pre- and post-treatment (at 12 weeks) VAS scores were 8.6 (range, 3–9) and 4.5 (range 2–4), respectively. In steroid group, mean pre- and post-treatment (at 12 weeks) VAS scores were 8.3 (range, 3–10) and 3.9 (range, 0–7), respectively. The difference was statistically significant within groups at baseline and 1 (P < 0.001) and 3 (P < 0.001) months after the injection.Conclusion:Subacromial injection of ketorolac has an equivalent outcome to subacromial injection of corticosteroid. The use of ketorolac injections can substantially decrease the pain and increase the range of motion of the shoulder and could be a reasonable alternative in case of corticosteroid contraindications.

show abstract

“…(1,2) Although SIS is generally self-limiting, the cuff lesions and complications caused by SIS often exacerbate over time and lead to debility and decreased quality of life (QoL) of SIS patients. (3,4) Many conservative treatment modalities have been demonstrated to be bene cial in relieving subacromial in ammation and shoulder pain and improving the shoulder functional status in SIS, (5)(6)(7)(8) including systemic nonsteroidal anti-in ammatory drugs (NSAIDs), physical therapy, activity modi cation, electromagnetic radiation, therapeutic exercises, and corticosteroid injections. There is wide agreement that NSAIDs treatment is the rst choice for stage I or II SIS.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Efficacy and Safety of Duloxetine and Nonsteroidal Anti-inflammatory Drugs in Subacromial Impingement Syndrome

Zhao¹,

Teng²,

Xu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Subacromialimpingement syndrome (SIS) is characterized by shoulder pain and restriction in range of motion (ROM), which lead to debility and decrease quality of life (QoL). Duloxetine could provide persistent long-term pain relief in chronic musculoskeletal pain. Therefore, we aimed to investigate the efficacy of duloxetine in stage I or II SIS patients through comparing the nonsteroidal anti-inflammatory drugs (NSAIDs) treatment.Methods: The patients diagnosed with stage I or II SISwere randomly assigned into the duloxetine group (N= 37) and NSAIDs group (N= 37). Duloxetine group patients started on oral duloxetine 40 mg per day for one week and then titrated up to 60 mg per day for one week. NSAIDs group patients received oral loxoprofen sodium tablets 60mg3 times a day for two weeks. The standard measures for investigating the efficacy include pain intensity (VAS), ROM, shoulder functional status, and the QoL at baseline, end of treatment, and at 1 and 3 months follow-up.Results: 74 eligible patients completed the treatment and evaluation. Both treatment groups improved significantly from baseline over time. And all parameters of pain intensity, shoulder functionalstatus and QoL in the duloxetine group were significantly better than those in the NSAIDs group.And no one manifested SIS recurrence and side effects during the entire follow-up period.Conclusions: Both duloxetine and NSAIDs can be beneficial in the rehabilitation of stage I or II SIS patients. Moreover, duloxetine resulted in improvements in outcomes greater than NSAIDs for the treatment of SIS. The current results indicated that duloxetine treatment might be used as a new safe and effective alternative for SIS. Given the encouraging results of this study, it would be worthwhile to confirm our findings in randomized placebo-controlled multicentre clinical trials.

show abstract

Lornoxicam injection is inferior to betamethasone in the treatment of subacromial impingement syndrome

Abstract: Although a single subacromial lornoxicam injection provides rapid functional recovery, which partially extends into the intermediate term, its results are inferior to betamethasone and it may be an alternative only in patients where corticosteroids are contraindicated.

Cited by 14 publications

References 37 publications

Comparison of Efficacy of Ketorolac, Triamcinolone and Betamethasone Injections in the Treatment of Shoulder Impingement Syndrome

Comparison of Efficacy of Ketorolac, Triamcinolone and Betamethasone Injections in the Treatment of Shoulder Impingement Syndrome

Comparison of subacromial ketorolac injection zversus corticosteroid injection in the treatment of shoulder impingement syndrome

Comparison of Efficacy and Safety of Duloxetine and Nonsteroidal Anti-inflammatory Drugs in Subacromial Impingement Syndrome

Contact Info

Product

Resources

About